Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 215184

In scope icon M 1 A
QID 215184 (Type "215184" in App Search)
A 72-year-old man presents to his primary care physician with a 2-month history of increasing urinary hesitancy. He says that he now needs to strain when beginning to void and tends to dribble after he finishes urinating. Recently, he also started having episodes of nocturia and increased day-time urinary frequency. His past medical history is significant for hypertension but he is not currently taking any medications because he does not like the side effects of the ones he has tried. His physician says that there is a medication that addresses both of his problems; however, he immediately experiences lightheadedness after starting the medication. Which of the following molecular changes would most likely be caused by this medication?

Decreased cyclic adenosine monophosphate production

16%

22/141

Decreased inositol phosphate production

45%

63/141

Increased cyclic adenosine monophosphate production

14%

20/141

Increased diacylglycerol production

6%

8/141

Increased inositol phosphate production

9%

13/141

Select Answer to see Preferred Response

bookmode logo Review TC In New Tab

This patient who presents with urinary hesitancy, nocturia, and dribbling most likely has benign prostatic hyperplasia, which in combination with hypertension can be treated with prazosin. This drug is an alpha-1-adrenergic inhibitor that decreases inositol phosphate production.

G-protein coupled receptors (GPCR) are cell surface receptors that serve as common mechanisms for intercellular signaling. Ligands bind to GPCRs and induce conformational changes that activate attached second messenger pathways. There are 3 common pathways used: Gq, Gs, and Gi. The Gq pathway activates phospholipase C to increase the production of inositol phosphate (IP3) and diacylglycerol. These products then activate protein kinase C and lead to downstream changes. Important receptors that use this pathway include alpha-1-adrenergic receptors, M3 muscarinic receptors, H1 histamine receptors, and V1 vasopressin receptors.

Illustration A shows the second messenger pathways downstream of Gs, Gi, and Gq receptors. As depicted, Gq activates phospholipase C to produce inositol phosphate and diacylglycerol.

Incorrect Answers:
Answer 1: Decreased cyclic adenosine monophosphate production would occur with drugs that inhibit the Gs second messenger pathway. This pathway is used by beta-adrenergic receptors as well as D1 dopamine receptors.

Answer 3: Increased cyclic adenosine monophosphate production would occur with drugs that inhibit the Gi second messenger pathway. This pathway is used by alpha-2-adrenergic receptors, M2 muscarinic receptors, and D2 dopamine receptors.

Answers 4-5: Increased diacylglycerol production and increased inositol phosphate production would occur with drugs that activate the Gq second messenger pathway. An example of an alpha-1-adrenergic pathway agonist is phenylephrine.

Bullet Summary:
The Gq second messenger pathway activates phospholipase C to increase the production of inositol phosphate and diacylglycerol.

ILLUSTRATIONS:
Authors
Rating
Please Rate Question Quality

2.5

  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon

(2)

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options